#USA #ADCs #Riverview #Piramal Pharma Solutions #Payload-Linker Suite

Piramal Pharma Solutions Launches Next-Gen Payload-Linker Suite

Piramal Pharma Solutions, a leader in Contract Development and Manufacturing Organizations (CDMO), has recently unveiled its state-of-the-art Payload-Linker Suite at its Riverview facility in Michigan. This move marks a significant milestone in the company’s $90 million investment plan aimed at enhancing manufacturing capacities across the U.S.

Located strategically in Riverview, the facility specializes in pharmaceutical active ingredients (APIs) and high-potency APIs (HPAPIs), offering tailor-made solutions for the development of linker technologies. The newly launched suite is set to revolutionize the way Piramal Pharma supports global development and production of payload-linkers. This technology is particularly crucial for complex therapies, including Antibody-Drug Conjugates (ADCs) and other bioconjugates, which are essential for targeted cancer treatments.

Peter DeYoung, the CEO of Piramal Global Pharma, emphasized the suite's importance by stating, "The introduction of our new Payload-Linker Suite in Riverview represents a significant achievement for PPS and our partners. It combines top-tier expertise, advanced technology, and industrial-scale linker manufacturing capabilities right here in Michigan, allowing our customers to accelerate the development and deployment of life-changing therapies such as ADCs."

This development aligns with Piramal’s commitment to deliver innovative solutions swiftly and reliably to patients worldwide. The Riverview location, known for over 60 years of experience in drug substance development and manufacturing, is now positioned as a key player in the linker supply chain for ADCelerate™, Piramal's integrated approach to Phase I ADC development.

The advanced technologies implemented within the Payload-Linker Suite—including containment, automation, and analytical capabilities—are aimed at streamlining the scalability of payload-linker programs. This innovation not only enhances the efficiency of their operations but also caters to the rising market demand for ADCs and other bioconjugate therapies.

Moreover, the company’s strategic expansions in Riverview and Lexington underline its commitment to becoming the preferred partner for companies looking to innovate in drug development and manufacturing within the U.S.

As Piramal Pharma Solutions continues to focus on tailored solutions for drug development, the new Payload-Linker Suite stands as a testament to their commitment to innovation and quality. By providing cutting-edge technology and manufacturing prowess, they are paving the way for complex therapies to reach the market faster while ensuring unparalleled efficiency and safety in the supply chain.

To stay ahead in the ever-evolving pharmaceutical landscape, Piramal Pharma Solutions is dedicated to enhancing their service offerings globally, creating patient-centered solutions across various therapeutic areas. This new suite reinforces their position as a frontrunner in the field, dedicated to crafting the future of medicine.

About Piramal Pharma Solutions

Piramal Pharma Solutions is a key player in the CDMO sector, offering end-to-end development and manufacturing solutions throughout the medicine lifecycle. The company serves clients through a globally integrated network across North America, Europe, and Asia, allowing them to deliver a full spectrum of services including drug research, pharmaceutical development, clinical trial supplies, and commercial API delivery.

With a strong commitment to innovation, Piramal also offers specialized services such as high-potency API development, ADC manufacturing, sterile fill-finish, peptide products, and solid oral dosage forms. The firm is also advancing in biologics development, capitalizing on investments that enhance capabilities in vaccines, gene therapies, and monoclonal antibodies.

For further details, visit Piramal Pharma Solutions.